- Emerging Drugs in the Treatment of Inflammatory Bowel Disease: Beyond Anti-TNF-alpha
-
Kim KO, Jang BI
- KMID: 1026364
- Korean J Gastroenterol.
- 2011 Nov;58(5):235-244.
- doi: 10.4166/kjg.2011.58.5.235
Understanding of the pathophysiology of inflammatory bowel disease (IBD) is constantly evolving and, recently, a number of biologic agents have been developed. They selectively target specific molecule or pathways and... -
- CITED
-
- Close
- SHARE
-
- Close
- Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics
-
Katsanos K, Papadakis
- KMID: 2412224
- Gut Liver.
- 2017 Jul;11(4):455-463.
- doi: 10.5009/gnl16308
Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some... -
- CITED
-
- Close
- SHARE
-
- Close
- Angiopoietin-1 variant, COMP-Ang1 attenuates hydrogen peroxide-induced acute lung injury
-
Kim SR, Lee KS, Park SJ, Min KH, Lee KY, Choe YH, Hong SH, Koh GY, Lee YC
- KMID: 756334
- Exp Mol Med.
- 2008 Jun;40(3):320-331.
- doi: 10.3858/emm.2008.40.3.320
Reactive oxygen species (ROS) play a crucial role in acute lung injury. Tissue inflammation, the increased vascular permeability, and plasma exudation are cardinal features of acute lung injury. Angiopoietin-1 (Ang1)... -
- CITED
-
- Close
- SHARE
-
- Close
